Lu AF35700

Drug Profile

Lu AF35700

Alternative Names: Lu-AF35700

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lundbeck A/S
  • Class Neuropsychotherapeutics
  • Mechanism of Action Dopamine D2 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Schizophrenia
  • Phase I Schizoaffective disorder

Most Recent Events

  • 25 Jul 2017 Phase-I clinical trials in Schizophrenia (In volunteers) in Germany (PO) (NCT03241147)
  • 20 Jul 2017 Lundbeck initiates enrolment in a phase II trial for Schizophrenia (Treatment-resistant) in USA (NCT03230864)
  • 16 Jun 2017 Lundbeck initiates enrolment in a phase I multiple dose pharmacokinetic trial (In volunteers) in United Kingdom (PO) (NCT03195946)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top